NuLife Sciences through is subsidiary announced their plan to commercialize their lead compound lyophilized Cytokine Concentrated Plasma in Ecuador.
NuLife Sciences (OTCQB:NULF) through is subsidiary announced their plan to commercialize their lead compound lyophilized Cytokine Concentrated Plasma in Ecuador.
As quoted in the press release:
The lyoCCP product is produced utilizing the NuLife Technique, the proprietary platform being developed by NuLife Sciences. The proprietary product has shown impressive results in aiding the healing of wounds that have been resistant to closure with traditional methods. An observational study was conducted earlier this year, showing impressive results in ten subjects. A larger study is planned in the coming weeks and months.
The worldwide wound care market is expected to be in excess of $20 billion by 2022. In fact, the worldwide incidence of all types of wounds ranges between 2% and 6%. These wounds represent a significant health risk, negatively impacting the quality of life for patients. In addition, they are very costly to healthcare systems.
“We are pleased with the study results and look forward to making an impact on the wound care market with our lyoCCP product,” said John Hollister, NuLife Sciences Chief Executive Officer.